Mechanistic and Molecular Study of the Process of Metastatic Dissemination in Colorectal Cancer

Study Overview
=================
Brief Summary
-----------------
To confirm the role of the collective dissemination in the mechanisms of tumoral invasion of colorectal cancers

Official Title
-----------------
Mechanistic and Molecular Study of the Process of Metastatic Dissemination in Colorectal Cancer

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Procedure: Sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Histological Diagnosis of stage IV colorectal cancer Hepatic metastasis and/or peritoneal potentially resecable Patient affiliated with a mode of the social security or recipient of such a mode Information of the patient or his legal representative and collection of his assent Exclusion Criteria: None metastatic colorectal cancer Cancer of appendicular origin Patients deprived of liberty or unable to give his assent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Patients with metastatic colorectal cancer<br>After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples. The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern: Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal Peritoneal liquid none tumoral peritoneum Portal blood Peripheral blood Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum. In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator. | Procedure: Sampling<br>* After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples. The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern: Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal Peritoneal liquid none tumoral peritoneum Portal blood Peripheral blood Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum. In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification and characterization of the tumoral intermediaries on the overflowing peritoneal | After several separation and centrifugation steps, clusters and tumor cells are isolated and counted in the various biological samples. The different isolated intermediates will be analyzed by immunolabeling with the antibodies directed against CK20, EpCAM, Vimentine and CD45. | Up to 24 months | 
| Identification and characterization of the tumoral intermediaries on the portal blood | After several separation and centrifugation steps, clusters and tumor cells are isolated and counted in the various biological samples. The different isolated intermediates will be analyzed by immunolabeling with the antibodies directed against CK20, EpCAM, Vimentine and CD45. | Up to 24 months | 
| Identification and characterization of the tumoral intermediaries on the peripheral blood | After several separation and centrifugation steps, clusters and tumor cells are isolated and counted in the various biological samples. The different isolated intermediates will be analyzed by immunolabeling with the antibodies directed against CK20, EpCAM, Vimentine and CD45. | Up to 24 months | 
| Identification and characterization of the tumoral intermediaries on the hepatic metastasis and/or peritoneal) | After several separation and centrifugation steps, clusters and tumor cells are isolated and counted in the various biological samples. The different isolated intermediates will be analyzed by immunolabeling with the antibodies directed against CK20, EpCAM, Vimentine and CD45. | Up to 24 months |